Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MC220503 Randomized Phase II Rescuing Cancer Immunotherapy With Plasma Exchange in Bladder Cancer 1 (ReCIPE-B1)

NCT07087860 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT07087860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07087860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MC220503 Randomized Phase II Rescuing Cancer Immunotherapy With Plasma Exchange in Bladder Cancer 1 (ReCIPE-B1)
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Recruiting
Start date
August 1, 2025
Completion date
August 7, 2028
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic bladder urothelial carcinoma, metastatic renal pelvis and ureter urothelial carcinoma, refractory bladder urothelial carcinoma, refractory renal pelvis and ureter urothelial carcinoma, stage iv bladder cancer ajcc v7, stage iv renal pelvis and ureter cancer ajcc v7